254 related articles for article (PubMed ID: 10903605)
41. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
42. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
[TBL] [Abstract][Full Text] [Related]
43. Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review.
Platsouka E; Zissis NP; Portolos J; Paniara O
J Chemother; 2003 Feb; 15(1):27-30. PubMed ID: 12678410
[TBL] [Abstract][Full Text] [Related]
44. Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.
Chan JD; Dellit TH; Lynch JB
J Intensive Care Med; 2018 Feb; 33(2):134-141. PubMed ID: 28486867
[TBL] [Abstract][Full Text] [Related]
45. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
[TBL] [Abstract][Full Text] [Related]
46. [Enterobacteriaceae susceptibility to piperacillin/tazobactam in a Chilean pediatric hospital].
Vega JR; Benadof D; Veas A; Acuña M
Rev Chilena Infectol; 2017 Dec; 34(6):563-569. PubMed ID: 29488550
[TBL] [Abstract][Full Text] [Related]
47. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
[TBL] [Abstract][Full Text] [Related]
48. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
[TBL] [Abstract][Full Text] [Related]
49. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
50. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
[TBL] [Abstract][Full Text] [Related]
51. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
[TBL] [Abstract][Full Text] [Related]
53. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Aynioglu A; Mutlu B; Hacihanefioglu A
Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
[TBL] [Abstract][Full Text] [Related]
54. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population.
Pratt JA; Stricherz MK; Verghese PS; Burke MJ
Pediatr Blood Cancer; 2014 Feb; 61(2):366-8. PubMed ID: 24038944
[TBL] [Abstract][Full Text] [Related]
55. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection.
Yoshioka K; Youngs DJ; Keighley MR
Infection; 1991; 19(1):25-9. PubMed ID: 2013505
[TBL] [Abstract][Full Text] [Related]
56. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.
Polk HC; Fink MP; Laverdiere M; Wilson SE; Garber GE; Barie PS; Hebert JC; Cheadle WG
Am Surg; 1993 Sep; 59(9):598-605. PubMed ID: 8396374
[TBL] [Abstract][Full Text] [Related]
57. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
[TBL] [Abstract][Full Text] [Related]
58. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections.
Shyr YM; Lui WY; Su CH; Wang LS; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Aug; 56(2):102-8. PubMed ID: 7553416
[TBL] [Abstract][Full Text] [Related]
59. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Lucasti C; Hershberger E; Miller B; Yankelev S; Steenbergen J; Friedland I; Solomkin J
Antimicrob Agents Chemother; 2014 Sep; 58(9):5350-7. PubMed ID: 24982069
[TBL] [Abstract][Full Text] [Related]
60. Antibiotics as first-line therapy for acute appendicitis: evidence for a change in clinical practice.
Coccolini F; Pisano M; Magnone S; Colaianni N; Campanati L; Catena F; Ansaloni L
World J Surg; 2012 Dec; 36(12):2952-3. PubMed ID: 22875010
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
